Hidradenitis suppurativa is a dermatological disorder which develops pimples, folliculitis, boils and deep-acne like cysts and blackheads. The pimples grow deeply in the skin and becomes painful in severe cases. Smoking and obesity are the most common risk factors of hidradenitis suppurativa. It is more prevalent in women compared to men. Hidradenitis suppurativa generally occurs in areas like underarms, groin, buttocks, upper thighs and breasts. Treatment and medications, such as antibiotics, corticosteroids, oral retinoids, acne washes, bleach bath, radiation therapy, hormone therapy and surgery, can clear or reduce the breakouts, remove scars and prevent occurrence of new breakouts. Company like XBiotech Inc. is in the process of development of MABp1, a True Human antibody, targets interleukin-1 alpha (IL-1α) for the treatment of hidradenitis suppurativa. Moreover, Amgen Inc., and Magellan Health Inc. are also involved in the development of therapeutic agents for hidradenitis suppurativa.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.